Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Skin Neoplasms 2Stomach Neoplasms 1Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinogenesis 1Breast Neoplasms 1

Interventions

aldesleukin 15pembrolizumab 11Cyclophosphamide 9fludarabine phosphate 7fludarabine 6Nivolumab 6Interleukin-2 6atezolizumab 5Radiotherapy 5Ipilimumab 4Interferon-alpha 4Drug Therapy 4Blood Specimen Collection 4Radiosurgery 3tremelimumab 2temsirolimus 2durvalumab 2cemiplimab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Paclitaxel 2Metformin 2Interleukin-12 Subunit p35 2Genistein 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Cetuximab 2zanolimumab 1vivitrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Poly I-C × Dermatologic × Clear all
NCT00094003 2005-11-11

Study of NS-9 in Patients With Liver Metastases

NS Pharma, Inc.

Phase 1 Completed
20 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡